Your browser doesn't support javascript.
loading
Feasibility of controlling hepatitis E in Jiangsu Province, China: a modelling study.
Yang, Meng; Cheng, Xiao-Qing; Zhao, Ze-Yu; Li, Pei-Hua; Rui, Jia; Lin, Sheng-Nan; Xu, Jing-Wen; Zhu, Yuan-Zhao; Wang, Yao; Liu, Xing-Chun; Luo, Li; Deng, Bin; Liu, Chan; Huang, Jie-Feng; Yang, Tian-Long; Li, Zhuo-Yang; Liu, Wei-Kang; Liu, Wen-Dong; Zhao, Ben-Hua; He, Yue; Yin, Qi; Mao, Si-Ying; Su, Yan-Hua; Zhang, Xue-Feng; Chen, Tian-Mu.
Afiliação
  • Yang M; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Cheng XQ; Jiangsu Center for Disease Control and Prevention, Nanjing City, Jiangsu Province, People's Republic of China.
  • Zhao ZY; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Li PH; Cirad, UMR 17, Intertryp, Université de Montpellier, 34398, Montpellier, France.
  • Rui J; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Lin SN; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Xu JW; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Zhu YZ; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Wang Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Liu XC; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Luo L; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Deng B; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Liu C; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Huang JF; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Yang TL; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Li ZY; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Liu WK; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Liu WD; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Zhao BH; Jiangsu Center for Disease Control and Prevention, Nanjing City, Jiangsu Province, People's Republic of China.
  • He Y; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Yin Q; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Mao SY; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Su YH; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China.
  • Zhang XF; State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, 4221-117 South Xiang'an Road, Xiang'an District, Xiamen City, 361102, Fujian Province, People's Republic of China. suyanhua813@xmu.edu.cn.
  • Chen TM; Jiangsu Center for Disease Control and Prevention, Nanjing City, Jiangsu Province, People's Republic of China. 784861714@qq.com.
Infect Dis Poverty ; 10(1): 91, 2021 Jun 29.
Article em En | MEDLINE | ID: mdl-34187566
BACKGROUND: Hepatitis E, an acute zoonotic disease caused by the hepatitis E virus (HEV), has a relatively high burden in developing countries. The current research model on hepatitis E mainly uses experimental animal models (such as pigs, chickens, and rabbits) to explain the transmission of HEV. Few studies have developed a multi-host and multi-route transmission dynamic model (MHMRTDM) to explore the transmission feature of HEV. Hence, this study aimed to explore its transmission and evaluate the effectiveness of intervention using the dataset of Jiangsu Province. METHODS: We developed a dataset comprising all reported HEV cases in Jiangsu Province from 2005 to 2018. The MHMRTDM was developed according to the natural history of HEV cases among humans and pigs and the multi-transmission routes such as person-to-person, pig-to-person, and environment-to-person. We estimated the key parameter of the transmission using the principle of least root mean square to fit the curve of the MHMRTDM to the reported data. We developed models with single or combined countermeasures to assess the effectiveness of interventions, which include vaccination, shortening the infectious period, and cutting transmission routes. The indicator, total attack rate (TAR), was adopted to assess the effectiveness. RESULTS: From 2005 to 2018, 44 923 hepatitis E cases were reported in Jiangsu Province. The model fits the data well (R2 = 0.655, P < 0.001). The incidence of the disease in Jiangsu Province and its cities peaks are around March; however, transmissibility of the disease peaks in December and January. The model showed that the most effective intervention was interrupting the pig-to-person route during the incidence trough of September, thereby reducing the TAR by 98.11%, followed by vaccination (reducing the TAR by 76.25% when the vaccination coefficient is 100%) and shortening the infectious period (reducing the TAR by 50.05% when the infectious period is shortened to 15 days). CONCLUSIONS: HEV could be controlled by interrupting the pig-to-person route, shortening the infectious period, and vaccination. Among these interventions, the most effective was interrupting the pig-to-person route.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Zoonoses / Hepatite E Tipo de estudo: Prognostic_studies Limite: Animals / Humans País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Zoonoses / Hepatite E Tipo de estudo: Prognostic_studies Limite: Animals / Humans País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article